Dr. Rina Patel-Trujillo, DO
NPI: 1548421571
Total Payments
$77,508
2024 Payments
$18,766
Companies
17
Transactions
270
Medicare Patients
1,332
Medicare Billing
$117,375
Payment Breakdown by Category
Other$65,100 (84.0%)
Travel$5,222 (6.7%)
Food & Beverage$5,146 (6.6%)
Consulting$2,040 (2.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $65,100 | 61 | 84.0% |
| Travel and Lodging | $5,222 | 35 | 6.7% |
| Food and Beverage | $5,146 | 173 | 6.6% |
| Consulting Fee | $2,040 | 1 | 2.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $73,362 | 178 | $0 (2024) |
| Novo Nordisk Inc | $2,169 | 7 | $0 (2021) |
| Insulet Corporation | $679.04 | 29 | $0 (2024) |
| Medtronic, Inc. | $215.07 | 4 | $0 (2024) |
| Xeris Pharmaceuticals, Inc. | $201.54 | 6 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $152.64 | 10 | $0 (2018) |
| Dexcom, Inc. | $142.64 | 6 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $131.59 | 9 | $0 (2022) |
| UCB, Inc. | $98.72 | 1 | $0 (2019) |
| GlaxoSmithKline, LLC. | $77.87 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $18,766 | 65 | Lilly USA, LLC ($18,369) |
| 2023 | $24,822 | 81 | Lilly USA, LLC ($24,199) |
| 2022 | $30,849 | 70 | Lilly USA, LLC ($30,579) |
| 2021 | $2,157 | 7 | Novo Nordisk Inc ($2,040) |
| 2020 | $61.99 | 2 | Dexcom, Inc. ($41.85) |
| 2019 | $232.77 | 8 | UCB, Inc. ($98.72) |
| 2018 | $453.25 | 26 | Lilly USA, LLC ($154.22) |
| 2017 | $166.16 | 11 | AstraZeneca Pharmaceuticals LP ($71.13) |
All Payment Transactions
270 individual payment records from CMS Open Payments — Page 2 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/19/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $875.00 | General |
| Category: Diabetes | ||||||
| 08/14/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $116.35 | General |
| Category: Diabetes | ||||||
| 07/31/2024 | Lilly USA, LLC | JARDIANCE (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $14.73 | General |
| Category: Diabetes | ||||||
| 07/25/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), BEXSERO | Food and Beverage | In-kind items and services | $16.22 | General |
| Category: VACCINES | ||||||
| 06/27/2024 | Insulet Corporation | Omnipod (Device) | Food and Beverage | Cash or cash equivalent | $22.56 | General |
| Category: Insulin Pump | ||||||
| 06/24/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $7.33 | General |
| Category: Diabetes | ||||||
| 06/04/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Diabetes | ||||||
| 06/03/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Diabetes | ||||||
| 06/03/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Diabetes | ||||||
| 06/03/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $26.42 | General |
| Category: Durable Pump | ||||||
| 05/17/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Diabetes | ||||||
| 05/14/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $18.88 | General |
| Category: DIABETES | ||||||
| 05/13/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Diabetes | ||||||
| 05/06/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $15.44 | General |
| Category: Diabetes Care | ||||||
| 05/01/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Diabetes | ||||||
| 04/25/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Diabetes | ||||||
| 04/22/2024 | PFIZER INC. | PAXLOVID (Drug) | Food and Beverage | In-kind items and services | $15.39 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 04/09/2024 | Insulet Corporation | Omnipod (Device) | Food and Beverage | Cash or cash equivalent | $108.54 | General |
| Category: Insulin Pump | ||||||
| 03/19/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $19.21 | General |
| Category: Diabetes | ||||||
| 03/18/2024 | Insulet Corporation | Omnipod (Device) | Food and Beverage | Cash or cash equivalent | $12.14 | General |
| Category: Insulin Pump | ||||||
| 02/20/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), BEXSERO | Food and Beverage | In-kind items and services | $24.80 | General |
| Category: VACCINES | ||||||
| 02/16/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Travel and Lodging | Cash or cash equivalent | $134.00 | General |
| Category: Diabetes | ||||||
| 02/16/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $62.99 | General |
| Category: Diabetes | ||||||
| 02/16/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $33.23 | General |
| Category: Diabetes | ||||||
| 02/16/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $21.63 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 253 | 342 | $36,425 | $22,546 |
| 2022 | 6 | 314 | 391 | $44,967 | $27,623 |
| 2021 | 7 | 398 | 512 | $65,495 | $38,277 |
| 2020 | 7 | 367 | 448 | $62,981 | $28,930 |
Total Patients
1,332
Total Services
1,693
Medicare Billing
$117,375
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 141 | 186 | $18,286 | $12,132 | 66.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 26 | 40 | $5,760 | $4,185 | 72.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 43 | 43 | $6,812 | $3,931 | 57.7% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Facility | 2023 | 28 | 56 | $4,368 | $1,467 | 33.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 15 | 17 | $1,199 | $832.16 | 69.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 127 | 156 | $15,025 | $9,685 | 64.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 65 | 91 | $12,384 | $8,777 | 70.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 53 | 53 | $8,215 | $4,589 | 55.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 20 | 20 | $3,980 | $2,627 | 66.0% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Facility | 2022 | 38 | 60 | $4,680 | $1,501 | 32.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 11 | 11 | $683.00 | $442.63 | 64.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 120 | 161 | $23,207 | $14,792 | 63.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 139 | 183 | $17,828 | $12,465 | 69.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 44 | 44 | $7,271 | $3,864 | 53.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 24 | 24 | $4,941 | $3,303 | 66.8% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Facility | 2021 | 36 | 61 | $4,737 | $1,630 | 34.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 20 | 23 | $5,135 | $1,514 | 29.5% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 15 | 16 | $2,376 | $708.39 | 29.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 122 | 163 | $21,839 | $11,920 | 54.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 108 | 131 | $12,436 | $7,472 | 60.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 43 | 45 | $12,720 | $2,742 | 21.6% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 28 | 28 | $4,340 | $2,581 | 59.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 21 | 21 | $4,179 | $2,068 | 49.5% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Facility | 2020 | 22 | 37 | $2,886 | $984.87 | 34.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 11 | 11 | $2,211 | $708.95 | 32.1% |
About Dr. Rina Patel-Trujillo, DO
Dr. Rina Patel-Trujillo, DO is a Endocrinology, Diabetes & Metabolism healthcare provider based in Albuquerque, New Mexico. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/23/2008. The National Provider Identifier (NPI) number assigned to this provider is 1548421571.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rina Patel-Trujillo, DO has received a total of $77,508 in payments from pharmaceutical and medical device companies, with $18,766 received in 2024. These payments were reported across 270 transactions from 17 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($65,100).
As a Medicare-enrolled provider, Patel-Trujillo has provided services to 1,332 Medicare beneficiaries, totaling 1,693 services with total Medicare billing of $117,375. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Albuquerque, NM
- Active Since 06/23/2008
- Last Updated 06/24/2015
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1548421571
Products in Payments
- MOUNJARO (Drug) $68,239
- Saxenda (Drug) $2,040
- Omnipod (Device) $679.04
- MINIMED 780G (Device) $215.07
- GVOKE PFS (Drug) $182.33
- FARXIGA (Drug) $123.30
- JARDIANCE (Drug) $114.01
- TRULICITY (Drug) $97.06
- HUMULIN (Drug) $92.36
- Ozempic (Drug) $85.37
- Dexcom G6 Transmitter (Medical Supply) $81.54
- TOUJEO (Drug) $58.97
- SOLIQUA (Drug) $51.31
- JANUVIA (Drug) $50.35
- Minimed 670G System (Device) $44.11
- Victoza (Drug) $44.11
- DEXCOM G6 CGM SYSTEM (Device) $41.85
- SHINGRIX (Biological) $41.02
- AREXVY (Drug) $36.85
- BEVESPI AEROSPHERE (Drug) $29.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Albuquerque
Robert Ferraro, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $159,919
Endocrinology, Diabetes & Metabolism $159,919
Jeremy Gleeson, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $79,052
Endocrinology, Diabetes & Metabolism $79,052
David Schade
Endocrinology, Diabetes & Metabolism — Payments: $41,921
Endocrinology, Diabetes & Metabolism $41,921
Ivan Pinon, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $38,194
Endocrinology, Diabetes & Metabolism $38,194
Patricia Kapsner, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $22,142
Endocrinology, Diabetes & Metabolism $22,142
Neil Kaminsky, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $17,617
Endocrinology, Diabetes & Metabolism $17,617